Drug intelligence / Profile preview

ST-1839

Development stage: Unknown
Lead developer: Beijing Scitech-Mq Pharmaceuticals
Modality: Small Molecules

Overview

ST-1839 is a small-molecule inhibitor of the RET (Rearranged during Transfection) tyrosine kinase, developed by Beijing Scitech-Mq Pharmaceuticals. It is specifically designed to target RET-resistant malignant tumors, which are cancers that have developed resistance to earlier generations of RET inhibitors. The drug is primarily being developed for the treatment of non-small cell lung cancer (NSCLC) and thyroid cancer harboring RET alterations. ST-1839 is currently in Phase 1 clinical development to evaluate its safety, tolerability, and preliminary efficacy in patients with these resistant malignancies.

Targets

RET (Rearranged during transfection receptor tyrosine kinase)

Beyond the preview

Go deeper on ST-1839.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ST-1839.

Explore the full profile